Have a personal or library account? Click to login

Modulation of brain glutamate dehydrogenase as a tool for controlling seizures

Acta Pharmaceutica
Volume 65 (2015): Issue 4 (December 2015)
By:
Open Access
|Dec 2015

References

  1. 1. H. S. White, M. D. Smith and K. S. Wilcox, Mechanisms of action of antiepileptic drugs, Int. Rev. Neurobiol. 81 (2007) 85-110; DOI: 10.1016/S0074-7742(06)81006-82.
    Search in Google Scholar
  2. 2. B. S. Meldrum, The role of glutamate in epilepsy and other CNS disorders, Neurology 44 (1994) S14-S23.
    Search in Google Scholar
  3. 3. U . Heinemann, D. Kaufer and A. Friedman, Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy, Glia 60 (2012) 1251-1257; DOI: 10.1002/glia.22311.10.1002/glia.22311361524822378298
    Search in Google Scholar
  4. 4. D. A. Coulter and T. Eid, Astrocytic regulation of glutamate homeostasis in epilepsy, Glia 60 (2012) 1215-1226; DOI: 10.1002/glia.22341.10.1002/glia.22341337538622592998
    Search in Google Scholar
  5. 5. A. Vezzani, J. French, T. Bartfai and T. Z. Baram, The role of inflammation in epilepsy, Nat. Rev. Neurol. 7 (2011) 31-40; DOI: 10.1038/nrneurol.2010.178.10.1038/nrneurol.2010.178337805121135885
    Search in Google Scholar
  6. 6. R . M. Kaminski, M. A. Rogawski and H. Klitgaard, The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments, Neurotherapeutics 11 (2014) 385-400; DOI: 10.1007/s13311-014-0266-1.10.1007/s13311-014-0266-1399612524671870
    Search in Google Scholar
  7. 7. H. E. Scharfman, Neuroscience. Metabolic control of epilepsy, Science 347 (2015) 1312-1313; DOI: 10.1126/science.aaa9607.10.1126/science.aaa960725792315
    Search in Google Scholar
  8. 8. N . Sada, S. Lee, T. Katsu, T. Otsuki and T. Inoue, Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy, Science 347 (2015) 1362-1367; DOI: 10.1126/science.aaa1299.10.1126/science.aaa129925792327
    Search in Google Scholar
  9. 9. B. S. Meldrum and M. A. Rogawski, Molecular targets for antiepileptic drug development, Neurotherapeutics 4 (2007) 18-61.10.1016/j.nurt.2006.11.010185243617199015
    Search in Google Scholar
  10. 10. A. Plaitakis, P. Flessas, A. B. Natsiou and P. Shashidharan, Glutamate dehydrogenase deficiency in cerebellar degenerations: clinical, biochemical and molecular genetic aspects, Can. J. Neurol. Sci. 20 (1993) S109-S116.10.1017/S0317167100048617
    Search in Google Scholar
  11. 11. G. H. Malthankar-Phatak, N. de Lanerolle, T. Eid, D. D. Spencer, K. L. Behar, S. S. Spencer, J. H. Kim and J. C. Lai, Differential glutamate dehydrogenase (GDH) activity profile in patients with temporal lobe epilepsy, Epilepsia 47 (2006) 1292-1299; DOI: 10.1111/j.1528-1167.2006.00543.x.10.1111/j.1528-1167.2006.00543.x16922873
    Search in Google Scholar
  12. 12. D. M. Raizen, A. Brooks-Kayal, L. Steinkrauss, G. I. Tennekoon, C. A. Stanley and A. Kelly, Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations, J. Pediatr. 146 (2005) 388-394; DOI: 10.1016/j.jpeds.2004.10.040.10.1016/j.jpeds.2004.10.04015756227
    Search in Google Scholar
  13. 13. S . Balasubramaniam, R. Kapoor, J. H. Yeow, P. G. Lim, S. Flanagan, S. Ellard and K. Hussain, Biochemical evaluation of an infant with hypoglycemia resulting from a novel de novo mutation of the GLUD1 gene and hyperinsulinism-hyperammonemia syndrome, J. Pediatr. Endocrinol. Metab. 24 (2011) 573-577.10.1515/jpem.2011.057
    Search in Google Scholar
  14. 14. N . Bahi-Buisson, E. Roze, C. Dionisi, F. Escande, V. Valayannopoulos, F. Feillet, C. Heinrichs, B. Chadefaux-Vekemans, B. Dan and P. de Lonlay, Neurological aspects of hyperinsulinism-hyperammonaemia syndrome, Dev. Med. Child. Neurol. 50 (2008) 945-949; DOI: 10.1111/j.1469-8749. 2008.03114.x.
    Search in Google Scholar
  15. 15. K. Aso, Y. Okano, T. Takeda, O. Sakamoto, K. Ban, K. Iida, T. Yamano and H. Shintaku, Spectrum of glutamate dehydrogenase mutations in Japanese patients with congenital hyperinsulinism and hyperammonemia syndrome, Osaka City Med. J. 57 (2011) 1-9.
    Search in Google Scholar
  16. 16. A. L. Sherwin, Neuroactive amino acids in focally epileptic human brain: a review, Neurochem. Res. 24 (1999) 1387-1395; DOI: 10.1023/A:1022580506443.10.1023/A:1022580506443
    Search in Google Scholar
  17. 17. L. A. Vega Rasgado, G. Ceballos Reyes G and F. Vega-Diaz, Anticonvulsant drugs, brain glutamate dehydrogenase activity and oxygen consumption, ISRN Pharmacol. 2012 (2012) 295853-295860.10.5402/2012/295853
    Search in Google Scholar
  18. 18. L. A. Vega Rasgado, G. Ceballos Reyes G and F. Vega-Díaz, Effect of convulsant drugs in GDH activity and oxygen consumption in mouse brain, J. Med. Med. Sci. 4 (2013) 34-42
    Search in Google Scholar
  19. 19. H. J. Strecker, Glutamic dehydrogenase, Arch. Biochem. Biophys. 46 (1953) 128-140; DOI: 10.1016/0003-9861(53)90176-3. 10.1016/0003-9861(53)90176-3
    Search in Google Scholar
DOI: https://doi.org/10.1515/acph-2015-0033 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 443 - 452
Accepted on: Jul 14, 2015
Published on: Dec 17, 2015
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
GDH,
antiepileptics,
oxygen consumption,
GABA,
glutamate
Related subjects:
Pharmacy,
Pharmacy, other

© 2015 Lourdes A. Vega Rasgado, Guillermo Ceballos Reyes, Fernando Vega Díaz, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 65 (2015): Issue 4 (December 2015)Next article